Australia - angielski - Department of Health (Therapeutic Goods Administration)

ipca pharma (australia) pty ltd - ciprofloxacin, quantity: 500 mg - tablet, film coated - excipient ingredients: maize starch; microcrystalline cellulose; sodium starch glycollate; colloidal anhydrous silica; magnesium stearate; hypromellose; purified talc; macrogol 4000; titanium dioxide - ciprofloxacin is indicated for treatment of infections caused by susceptible organisms in the conditions listed below: urinary tract infections; gonorrhoeal urethritis and cervicitis; gastroenteritis; bronchial infections; skin and skin structure infections; bone and joint infections; chronic bacterial prostatitis of mild or moderate severity. inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolised bacillus anthracis. ciprofloxacin serum concentrations achieved in humans serve as a surrogate endpoint reasonably likely to predict clinical benefit and provide the basis for this indication. note: 1. typhoid and paratyphoid infections and infections due to multi-resistant staphylococcus aureus are excluded from the above due to insufficient data. 2. because gram-positive organisms are generally less sensitive to ciprofloxacin, it may not be the drug of choice in cases with gram-positive infections, such as pneumonia due to streptococcus pneumoniae. 3. chronic bacterial prostatitis should be demonstrated by microbiological evidence localising infection to the prostate. strains of neisseria gonorrhoea resistant to ciprofloxacin have been reported in australia. appropriate culture and susceptibility tests should be performed before treatment in order to determine organism susceptibility to ciprofloxacin and after treatment as warranted by the clinical condition. therapy with ciprofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. ciprofloxacin is suitable to treat mixed infections caused by susceptible strains of both gram-negative and gram-positive aerobic bacteria. if anaerobic organisms are suspected as accompanying aetiologic agents, additional therapy should be considered.

Australia - angielski - Department of Health (Therapeutic Goods Administration)

ipca pharma (australia) pty ltd - ciprofloxacin, quantity: 250 mg - tablet, film coated - excipient ingredients: maize starch; microcrystalline cellulose; sodium starch glycollate; colloidal anhydrous silica; magnesium stearate; hypromellose; purified talc; macrogol 4000; titanium dioxide - ciprofloxacin is indicated for treatment of infections caused by susceptible organisms in the conditions listed below: urinary tract infections; gonorrhoeal urethritis and cervicitis; gastroenteritis; bronchial infections; skin and skin structure infections; bone and joint infections; chronic bacterial prostatitis of mild or moderate severity. inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolised bacillus anthracis. ciprofloxacin serum concentrations achieved in humans serve as a surrogate endpoint reasonably likely to predict clinical benefit and provide the basis for this indication. note: 1. typhoid and paratyphoid infections and infections due to multi-resistant staphylococcus aureus are excluded from the above due to insufficient data. 2. because gram-positive organisms are generally less sensitive to ciprofloxacin, it may not be the drug of choice in cases with gram-positive infections, such as pneumonia due to streptococcus pneumoniae. 3. chronic bacterial prostatitis should be demonstrated by microbiological evidence localising infection to the prostate. strains of neisseria gonorrhoea resistant to ciprofloxacin have been reported in australia. appropriate culture and susceptibility tests should be performed before treatment in order to determine organism susceptibility to ciprofloxacin and after treatment as warranted by the clinical condition. therapy with ciprofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. ciprofloxacin is suitable to treat mixed infections caused by susceptible strains of both gram-negative and gram-positive aerobic bacteria. if anaerobic organisms are suspected as accompanying aetiologic agents, additional therapy should be considered.

Australia - angielski - Department of Health (Therapeutic Goods Administration)

nature's family australia pty ltd - royal jelly fresh -

Australia - angielski - Department of Health (Therapeutic Goods Administration)

nature's family australia pty ltd - betacarotene,calcium ascorbate dihydrate,colecalciferol,calcium carbonate,cyanocobalamin,d-alpha-tocopherol,ferrous fumarate,fish oil - rich in omega-3 acids,folic acid,magnesium oxide,nicotinamide,pyridoxine hydrochloride,potassium iodide,riboflavin,thiamine nitrate,zinc sulfate monohydrate -

Australia - angielski - Department of Health (Therapeutic Goods Administration)

nature's family australia pty ltd - ct772 - severe acute respiratory syndrome-associated coronavirus ivds - intended to detect the novel coronavirus sars-cov-2 that causes covid-19, for self-testing by lay persons (anterior nasal swabs).

Australia - angielski - Department of Health (Therapeutic Goods Administration)

nature's family australia pty ltd - biotin,calcium pantothenate,cyanocobalamin,ferrous fumarate,folic acid,iodine,nicotinamide,pyridoxine,riboflavin,thiamine hydrochloride -

Australia - angielski - Department of Health (Therapeutic Goods Administration)

nature's family australia pty ltd - calcium,colecalciferol -

Australia - angielski - Department of Health (Therapeutic Goods Administration)

nature's family australia pty ltd - lecithin -

Australia - angielski - Department of Health (Therapeutic Goods Administration)

nature's family australia pty ltd - fish oil - rich in omega-3 acids -

Australia - angielski - Department of Health (Therapeutic Goods Administration)

nature's family australia pty ltd - ct772 - severe acute respiratory syndrome-associated coronavirus ivds - genbody covid-19 ag kit is an immunochromatographic assay for the qualitative detection of sars-cov-2 antigen in nasopharyngeal and oropharyngeal swab from human